Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of Toronto

$25,000.00

Synthesis of Modified Nucleotide Triphosphates for Enzymatic DNA Synthesis**

EF 2018-19

Résumé
DNA sequencing technology has dropped the price of reading DNA over 10,000 times in 10 years. The bottleneck of synthetic biology is now writing (i.e. synthesizing) DNA. Startups in three major economies (US, France, UK) are working on next-generation enzymatic DNA synthesis technology to replace the current chemical technology. Spindle Biotech is solely focused on developing Canadian technology for enzymatic DNA synthesis. Currently, the only commercially viable method is a two-step process developed in the 1970s. This method chemically synthesizes short DNA fragments and assembles them in an error-prone and time-consuming step. This process takes an order of magnitude longer and is responsible for an estimated 1,200,000 litres of hazardous chemical waste per year, including acetonitrile, trichloroacetic acid, toluene, tetrahydrofuran, and pyridine. Enzymatic DNA synthesis is the only way to reduce the cost and turnaround time for long synthetic DNA, which helps in accelerating vaccine production, engineering novel enzymes that have the ability to restrict cancer growth, producing sustainable biofuels, improving crop yield, and detecting and breaking down environmental pollutants in the soil, air, and water.*The proposed innovation is a set of sixteen protected deoxyribonucleotide triphosphates, corresponding to the each permutation of the four natural nucleotides with four protecting groups chosen from literature. The nucleotides will be synthesized at the University of Toronto, Scarborough. The nucleotides will be screened by Spindle Biotech Inc. at the JLABS incubator in downtown Toronto. Nucleotides against a library of enzymes and reaction conditions to optimize the DNA synthesis process. A number of starting points for the proposed syntheses have been identified. The industrial partner, Spindle Biotech Inc., is a Canadian-owned company solely focused on developing Canadian technology for enzymatic DNA synthesis. The nucleotides designed in this project will be incorporated into a DNA synthesizer being developed in parallel. The implications are far reaching, including public health and national security.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
536353-2018
Name nom
Kraatz, HeinzBernhard
Department département
Physical & Environmental Sciences (Scarborough)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5402
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Nucleic acids
Research subject fr
Acides nucléiques
Partie
1
Nb partie
1
Application title
Synthesis of Modified Nucleotide Triphosphates for Enzymatic DNA Synthesis**
Keyword
NSERC
Application summary
DNA sequencing technology has dropped the price of reading DNA over 10,000 times in 10 years. The bottleneck of synthetic biology is now writing (i.e. synthesizing) DNA. Startups in three major economies (US, France, UK) are working on next-generation enzymatic DNA synthesis technology to replace the current chemical technology. Spindle Biotech is solely focused on developing Canadian technology for enzymatic DNA synthesis. Currently, the only commercially viable method is a two-step process developed in the 1970s. This method chemically synthesizes short DNA fragments and assembles them in an error-prone and time-consuming step. This process takes an order of magnitude longer and is responsible for an estimated 1,200,000 litres of hazardous chemical waste per year, including acetonitrile, trichloroacetic acid, toluene, tetrahydrofuran, and pyridine. Enzymatic DNA synthesis is the only way to reduce the cost and turnaround time for long synthetic DNA, which helps in accelerating vaccine production, engineering novel enzymes that have the ability to restrict cancer growth, producing sustainable biofuels, improving crop yield, and detecting and breaking down environmental pollutants in the soil, air, and water.*The proposed innovation is a set of sixteen protected deoxyribonucleotide triphosphates, corresponding to the each permutation of the four natural nucleotides with four protecting groups chosen from literature. The nucleotides will be synthesized at the University of Toronto, Scarborough. The nucleotides will be screened by Spindle Biotech Inc. at the JLABS incubator in downtown Toronto. Nucleotides against a library of enzymes and reaction conditions to optimize the DNA synthesis process. A number of starting points for the proposed syntheses have been identified. The industrial partner, Spindle Biotech Inc., is a Canadian-owned company solely focused on developing Canadian technology for enzymatic DNA synthesis. The nucleotides designed in this project will be incorporated into a DNA synthesizer being developed in parallel. The implications are far reaching, including public health and national security.